Showing 2521-2530 of 4065 results for "".
- Clinical Data on Lumenis’ New Laser Hair Removal Solution Presented at ASLMS Conferencehttps://reachmd.com/news/clinical-data-on-lumenis-new-laser-hair-removal-solution-to-be-presented-at-aslms-conference/2474269/Lumenis Be. Ltd. unveiled the newest edition of its breakthrough dual-wavelength laser hair removal solution, SPLENDOR XTM ahead of the American Society for Laser Medicine and Surgery (ASLMS) Conference. SPLENDOR XTM is powered by Lumenis’ proprietary BLEND X® tec
- Almirall Hosts 16th Skin Academyhttps://reachmd.com/news/Almirall-Hosts-16th-Skin-Academy/2471810/Almirall held the 16th edition of its Skin Academy conference for healthcare professionals in the field of dermatology on March 22-23 at the Barcelona International Convention Center in Spain. The event featured a comprehensive program aimed at sharing state-of-the-art scientific knowledge
- Penny for Your Thoughts? Master Copper Regulator Discovery May Offer Alzheimer’s Clueshttps://reachmd.com/news/penny-for-your-thoughts-master-copper-regulator-discovery-may-offer-alzheimers-clues/2468229/New therapeutic opportunities often emerge from research on simple organisms. For instance, the 2020 Nobel Prize in Chemistry awarded to Emmanuelle Charpentier, Ph.D., and Jennifer Doudna, Ph.D., for their CRISPR-based DNA editing discovery began with studies using bacteria just a deca
- Budesonide Glycopyrronium Formoterol Improved Lung Function in Phase 3 Asthma Trialshttps://reachmd.com/news/budesonide-glycopyrronium-formoterol-improved-lung-function-in-phase-3-asthma-trials/2487270/Key Takeaways Multiplicity-adjusted primary lung-function endpoints were met in both studies, and lung function favored budesonide-glycopyrronium-formoterol 320/28.8/10 mcg across comparisons. Pooled severe exacerbation rates were lower versus the comb
- Fortitude Announces T‑Cell Bispecific Program for Axial Spondyloarthritishttps://reachmd.com/news/fortitude-announces-tcell-bispecific-program-for-axial-spondyloarthritis/2486540/Key points: Fortitude Biomedicines introduced a preclinical bispecific antibody targeting T-cell signaling in axial spondyloarthritis Company-reported animal data suggest selective and durable suppression of disease-associated T-cell activity
- Study Supports Safety, Efficacy of Subcutaneous Forehead Lift for Upper Facial Aginghttps://reachmd.com/news/study-supports-safety-efficacy-of-subcutaneous-forehead-lift-for-upper-facial-aging/2486458/A retrospective analysis published in Frontiers in Surgery evaluated the effectiveness and safety of subcutaneous forehead lift (SFL) for reducing horizontal forehead and glabellar wrinkles using the validated Wrinkle Assessment Scale (WAS). The study included 697 patients treated at a s
- Dermatology Residents Show Gains After Targeted Topical Formulation Educationhttps://reachmd.com/news/dermatology-residents-show-gains-after-targeted-topical-formulation-education/2486095/A small survey-based study found that dermatology residents from 3 training programs reported limited formal education in topical vehicle formulation science, but showed improved comfort, confidence, and knowledge after a targeted educational intervention.
- Triple‑Phytochemical Nanoparticle for CRC: Formulation, In Vitro Release, Safety, and Gene‑Expression Signalshttps://reachmd.com/news/triplephytochemical-nanoparticle-for-crc-formulation-in-vitro-release-safety-and-geneexpression-signals/2485787/Investigators report developing a triple-payload nanoparticle carrying resveratrol, acetyl-11-keto-β-boswellic acid (AKBA), and quercetin—referred to as the 3X nanoparticle formulation—for colore
- Octane Aesthetics Tech Forum: Strategy Over Syringes Leads 2025 Filler Reboundhttps://reachmd.com/news/octane-aesthetics-tech-forum-strategy-over-syringes-leads-2025-filler-rebound/2485717/“Flipping the Filler Script” was a hot topic at the 2026 Octane Aesthetics Tech Forum held January 8 and 9 in Newport Beach, California. The panel was moderated by Jason D. Bloom, MD, FACS, of Bloom Facial Plastic Surgery in Bryn Mawr, Pennsylvania, and panelists included Shawna Chrisman, NP, Chi
- Octane Aesthetics Tech Forum Panelists React to FDA Approval of Oral Semaglutidehttps://reachmd.com/news/octane-aesthetics-tech-forum-panelists-react-to-fda-approval-of-oral-semaglutide/2485572/At the 2026 Octane Aesthetics Tech Forum, panelists weighed in on the recent FDA approval of oral semaglutide, offering a mix of cautious optimism and clinical realism. While the approval marks a milestone in expanding GLP-1 receptor agonist (RA) access, most experts on the panel said oral versio